- Home
- EXC vs RMD Comparison
EXC vs RMD Comparison
Compare EXC & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXC
- RMD
- Stock Information
- Founded
- EXC 1999
- RMD 1989
- Country
- EXC United States
- RMD United States
- Employees
- EXC N/A
- RMD N/A
- Industry
- EXC Power Generation
- RMD Medical/Dental Instruments
- Sector
- EXC Utilities
- RMD Health Care
- Exchange
- EXC Nasdaq
- RMD Nasdaq
- Market Cap
- EXC 44.1B
- RMD 37.0B
- IPO Year
- EXC N/A
- RMD 1995
- Fundamental
- Price
- EXC $42.60
- RMD $253.67
- Analyst Decision
- EXC Buy
- RMD Buy
- Analyst Count
- EXC 11
- RMD 13
- Target Price
- EXC $47.64
- RMD $259.40
- AVG Volume (30 Days)
- EXC 6.8M
- RMD 673.2K
- Earning Date
- EXC 07-31-2025
- RMD 07-31-2025
- Dividend Yield
- EXC 3.76%
- RMD 0.84%
- EPS Growth
- EXC 15.84
- RMD 37.08
- EPS
- EXC 2.69
- RMD 8.91
- Revenue
- EXC $23,699,000,000.00
- RMD $5,021,529,000.00
- Revenue This Year
- EXC $6.06
- RMD $10.37
- Revenue Next Year
- EXC $2.71
- RMD $7.77
- P/E Ratio
- EXC $15.81
- RMD $28.16
- Revenue Growth
- EXC 6.72
- RMD 9.54
- 52 Week Low
- EXC $34.01
- RMD $179.42
- 52 Week High
- EXC $48.11
- RMD $263.05
- Technical
- Relative Strength Index (RSI)
- EXC 42.09
- RMD 62.53
- Support Level
- EXC $42.18
- RMD $248.72
- Resistance Level
- EXC $43.74
- RMD $254.03
- Average True Range (ATR)
- EXC 0.65
- RMD 3.62
- MACD
- EXC 0.01
- RMD -0.36
- Stochastic Oscillator
- EXC 27.53
- RMD 91.29
About EXC Exelon Corporation
Exelon serves approximately 10 million power and gas customers at its six regulated utilities in Illinois, Pennsylvania, Maryland, New Jersey, Delaware, and Washington, D.C.
About RMD ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.